| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443942 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
The previously demonstrated survival benefit for abiraterone is accompanied by improvements in patient-reported HRQoL and a significant delay in HRQoL deterioration when compared with prednisone.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stephen Harland, John Staffurth, Arturo Molina, Yanni Hao, Dennis D. Gagnon, Cora N. Sternberg, David Cella, Karim Fizazi, Christopher J. Logothetis, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono, Howard I. Scher,